Elebsiran not checked
Vir Biotechnology, Inc. · VIR-2218
FollowEvery change as it happens, and a Monday email
Trials
4 active
10 in total · 6 in the EU
Targets
—
None known yet
What this is
- How it works
- A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
- Tested for
- Viral Hepatitis (3 trials), Hepatitis D, Chronic
- Main trialPhase 3
- “This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.”In the company’s words, NCT06903338 on ClinicalTrials.gov
- Other names
- VIR-2218
Other drugs for Viral Hepatitis
- GST-HG141Fujian Akeylink Biotechnology Co., Ltd. · Phase 3
- AHB-137Ausper Biopharma Co., Ltd. · Phase 3
- Bemnifosbuvir/RuzasvirAtea Pharmaceuticals, Inc. · Phase 3
- TobevibartVir Biotechnology, Inc. · Phase 3
- In-House Recombinant Hepatitis B vaccinePT Bio Farma · Phase 3
- BrelovitugMirum Pharmaceuticals, Inc. · Phase 3
Coming up3
- DecPhase 3 trial completes · ClinicalTrials.gov
- Mar 2029Phase 2 trial completes · ClinicalTrials.gov
- Nov 2031Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovCompletion date moved: 2026-11 to 2029-03 · ClinicalTrials.gov NCT07142811
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Sep 2026 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | |
| Phase 3Active, not recruiting | Dec 2026 | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | |
| Phase 2Active, not recruiting | Mar 2029 | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | |
| Phase 2Active, not recruiting | Nov 2031 | SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. | |
| Phase 2Completed | 25 Mar 2024 | Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection | |
| Phase 2Completed | 16 Mar 2026 | Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection | |
| Phase 1/2Completed | 3 Sep 2020 | Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B | |
| Phase 1/2Completed | 15 Oct 2024 | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection | |
| Phase 1Completed | 1 Mar 2025 | A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 | |
| Phase 1Completed | 9 Dec 2025 | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026